QRay

Company Overview

Snapshot

Founded in December 2005, QRay operates with 1–10 employees. The company reached a significant milestone in September 2006 by initiating a skin treatment trial.

Business overview

QRay develops and manufactures patient-administered phototherapeutic devices designed for the treatment of chronic wounds and oral ulcers, as well as for the alleviation of chronic pain conditions. The company's core technology, Visible Light Therapy (VLT), utilizes the full spectrum of visible light bandwidths to create non-invasive, chemical-free solutions. QRay's flagship product, Vireo, is a phototherapy device based on VLT technology, offering preprogrammed and programmable therapies for healing and closing chronic wounds. The company serves markets within the Health Tech & Life Sciences sector, specifically focusing on medical devices and medical treatment & therapeutics.

Strategic signal

In September 2006, QRay commenced a skin treatment trial, indicating a critical step in validating its phototherapeutic devices. This development signals the company's progression from research and development into clinical application, demonstrating a commitment to bringing its VLT technology to market for chronic wound care.

Company Intelligence Q&A

What is QRay's primary focus?

QRay develops and manufactures home-based phototherapeutic devices for the treatment of chronic wounds and oral ulcers, and for alleviating chronic pain conditions.

What is the company's core technology?

QRay's core technology is Visible Light Therapy (VLT), which harnesses the full spectrum of visible light bandwidths for non-invasive treatment.

When was QRay founded?

QRay was founded in December 2005.

What is QRay's flagship product?

QRay's flagship product is Vireo, a fully adjustable, patient-friendly phototherapy device based on VLT technology designed for healing chronic wounds.

What significant development occurred in September 2006?

In September 2006, QRay began a skin treatment trial for its phototherapeutic devices.